China Manufacturer for Non Standard Amino Acids - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex

Short Description:

Send email to us

Product Detail

Product Tags

Feedback (2)

We now have our individual sales group, layout team, technical team, QC crew and package group. Now we have strict high-quality control procedures for each procedure. Also, all of our workers are experienced in printing discipline for Mercury Acetate, 5-Methoxyinsole, Nopyl Acetate, Let's cooperate hand in hand to jointly make a beautiful future. We sincerely welcome you to visit our company or contact us for cooperation!

China Manufacturer for Non Standard Amino Acids - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:

Product Detail

Name	Eptifibatide
CAS number	188627-80-7
Molecular formula	C35H49N11O9S2
Molecular weight	831.96
EINECS Number	641-366-7
Density	1.60±0.1 g/cm3(Predicted)
Storage conditions	Sealed in dry, store in freezer, under -15°C

Synonyms

Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).

Platelet Glycoprotein Antagonist

Etifibatide (integrilin) is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.

Classification

Classification of Antiplatelet Aggregation Drugs

Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.

Product detail pictures:

Related Product Guide:

To meet the customers' over-expected pleasure , now we have our potent staff to offer our greatest general service which includes internet marketing, sales, planning, output, quality controlling, packing, warehousing and logistics for China Manufacturer for Non Standard Amino Acids - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Doha, Indonesia, Armenia, Now, we professionally supplies customers with our main products And our business is not only the "buy" and "sell", but also focus on more. We target to be your loyal supplier and long-term cooperator in China. Now, We hope to be the friends with you.

1-Amino-4-Methylpiperazine